 CAMBRIDGE, Mass., March 17, 2022 GLOBE NEWSWIRE -- Evelo Biosciences, Inc. Nasdaq:EVLO, a clinical stage biotechnology company developing SINTAXTM medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 24, 2022 to report its fourth quarter and full year 2021 financial results and discuss business highlights. 